STOCK TITAN

Protect Pharmaceutical Embarks on Aggressive Growth

Protect Pharmaceutical Corp (OTC: PRTT) has initiated a turnaround strategy powered by its merger with PUMA, aiming to recover revenue levels of $100 million achieved by PUMA in 2012.

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Rhea-AI Summary

Protect Pharmaceutical Corp (OTC: PRTT) has initiated a turnaround strategy powered by its merger with PUMA, aiming to recover revenue levels of $100 million achieved by PUMA in 2012. The company has consolidated its assets, reducing debt to nearly zero, and plans to introduce innovative green technologies in biopolymers for packaging and industrial design. PRTT anticipates generating profits exceeding $500,000 on revenues of $6 million by the end of 2021, marking the beginning of its revenue growth trajectory.

Loading...
Loading translation...

Positive

  • Consolidated debt is close to zero.
  • Plans to introduce innovative green technologies in biopolymers.
  • Expected profit of over $500,000 on projected revenues of $6 million by end of 2021.

Negative

  • No significant historical revenue performance since PUMA's $100 million peak in 2012.
Argus Session date unavailable
+5.96% session move Open Argus
Details

News Market Reaction – PRTT

The recorded move for PRTT in the trading session of this news was +5.96%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Sevnica, Slovenia, March 10, 2021 (GLOBE NEWSWIRE) -- PROTECT PHARMACEUTICAL CORP. “OTC:(PRTT)” Powered by the merger with PUMA, Protect Pharmaceutical Corp has commenced strategies to bring the company back to the sales revenue previously enjoyed by PUMA of up to $100 million in annual revenue (which PUMA achieved in 2012).

The first step was a consolidation of assets to clear company debts. This has been achieved and at the moment the consolidated debt is close to zero. The second step is to return to significant volumes of revenue and profits by introducing more innovative and green technologies, occupying a market niche in the field of green biopolymers in packaging and industrial design. These products include: biodegradable films, packages, cups, funeral accessories (biodegradable coffins) and large-scale environmentally friendly food production, as well as animal feed and raw materials for biotechnology.

PRTT expects profits in excess of $500,000 by the end of 2021 based on revenues of $6 million. This would be the start of its revenue trajectory as it maximizes the already proven assets and strategies of PUMA.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For more information contact:
Protect Pharmaceutical Corp.
(801) 432-0405
info@agropharmacy.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Protect Pharmaceutical Corp's stock symbol?

Protect Pharmaceutical Corp's stock symbol is PRTT.

What is Protect Pharmaceutical Corp's revenue target for 2021?

The revenue target for Protect Pharmaceutical Corp in 2021 is $6 million.

What profit does Protect Pharmaceutical Corp expect by the end of 2021?

Protect Pharmaceutical Corp expects profits exceeding $500,000 by the end of 2021.

What technologies is Protect Pharmaceutical Corp focusing on?

Protect Pharmaceutical Corp is focusing on green technologies, particularly biopolymers for packaging and industrial design.

Keep reading